Halozyme reaffirms FY22 non-GAAP EPS view $2.10-$2.25, consensus $2.04

Reaffirms FY22 revenue view $655M-$658M, consensus $661.33M. FY22 guidance represents a growth of 48%-55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115M-$125M. The Company expects revenue from royalties to increase by approximately 70% over revenue from royalties in 2021, to approximately $350M-$360M. Reaffirms FY22 GAAP operating income of $240M-$265M, which includes one-time transaction costs of approximately $45M and amortization of approximately $80M related to the Antares acquisition. Adjusting for these costs, the company expects expect adjusted operating income of $365M-$390M. Sees FY22 GAAP diluted EPS $1.20-$1.35 due to acquisition related costs in 2022.